Do not use in dogs aged less than 12 months, or less than 18 months for exceptionally large breeds of dogs, such as Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer growth period.
Do not use Quiflor 20mg or 80mg in cats. For the treatment of this species, a 5 mg tablet is available.
Do not use Quiflor 5mg Tablets in cats aged less than 16 weeks.
Do not use in animals with known hypersensitivity to marbofloxacin or other (fluoro)quinolones or to any of the excipients of the product.
Do not use in cases of resistance against quinolones, since (almost) complete cross-resistance exists against other fluoroquinolones
Special precautions for safe use in animals
A low urinary pH could have an inhibitory effect on the activity of marbofloxacin. Pyoderma occurs mostly secondary to an underlying disease, thus, it is advisable to determine the underlying cause and to treat the animal accordingly.
High doses of some fluoroquinolones may have epileptogenic potential. Cautious use is recommended in dogs and cats diagnosed as suffering from epilepsy. However, at the therapeutic recommended dosage, no severe side-effects are to be expected in dogs and cats. Fluoroquinolones have been shown to induce erosion of articular cartilage in juvenile dogs and care should be taken to dose accurately especially in young animals. No lesions of the articular joints were encountered in clinical studies at the recommended dose rate.
Official and local antimicrobial policies should be taken in to account when the veterinary medicinal product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly to other classes of antimicrobials. Whenever possible, use of fluoroquinolones should be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the (fluoro)quinolones and may decrease effectiveness of treatment with other quinolones due to the potential for cross-resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to (fluoro)quinolones should avoid using this product.
In case of accidental ingestion seek medical attention and show product label and/or package leaflet to the doctor.
Wash hands after use.
Interactions
Fluoroquinolones are known to interact with orally administered cations (Aluminium, Calcium, Magnesium, Iron). In such cases, the bioavailability of marbofloxacin may be reduced. Concurrent administration of theophylline products may be followed by inhibited theophylline clearance.
Adverse events
Dogs: Very rare (<1 animal / 10 000 animals treated, including isolated reports): - Vomiting, soft faeces, Modification of thirst.
- Hyperactivity (Transient)
All adverse events listed above ceases spontaneously after treatment and do not necessitate cessation of treatment.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Overdose:
Overdosage may cause acute signs in the form of neurological disorders, which should be treated symptomatically.